Difference between revisions of "Part:BBa K5490028"

 
Line 1: Line 1:
  
 +
__NOTOC__
 +
<partinfo>BBa_K5490028 short</partinfo>
 +
It’s an inducible endonuclease protein that can target any RNA sequence complementary to a gRNA.
 +
It contains an HA tag for Western blot and Immunohistochemistry analysis, and a mchery reporter with an NLS for separating activity between CasRx and the target RNA.
 +
 +
 +
<!-- Add more about the biology of this part here
 +
===Usage and Biology===
 +
 +
<!-- -->
 +
<span class='h3bb'>Sequence and Features</span>
 +
<partinfo>BBa_K5490028 SequenceAndFeatures</partinfo>
 +
 +
 +
<!-- Uncomment this to enable Functional Parameter display
 +
===Functional Parameters===
 +
<partinfo>BBa_K5490028 parameters</partinfo>
 +
<!-- -->
 +
ecision in targeting specific RNA sequences. As a viral protein, CasRx operates independently of the host's cellular machinery, which reduces variability and enhances efficiency.
 +
 +
CasRx is the smallest member of the RNA-targeting CRISPR family, allowing for easier delivery into cells while maintaining high specificity and efficiency in cleaving target RNA. Its minimal off-target effects and high efficiency make it ideal for large-scale transcriptome screening, precise gene silencing, and targeting viral RNA in therapeutic applications.
 +
 +
A key advantage of CasRx over other CRISPR systems is its simplicity--it does not require a PAM sequence or a tracrRNA, making it one of the most straightforward CRISPR systems to implement. CasRx can target virtually any RNA sequence when paired with a guide RNA (gRNA) that is complementary to the target.
 +
 +
 +
Konermann S, Lotfy P, Brideau NJ, Oki J, Shokhirev MN, Hsu PD. Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors. Cell. 2018 Apr 19;173(3):665-676.e14. doi: 10.1016/j.cell.2018.02.033. Epub 2018 Mar 15. PMID: 29551272; PMCID: PMC5910255.
 +
Chuang YF, Wang PY, Kumar S, Lama S, Lin FL, Liu GS. Methods for in vitro CRISPR/CasRx-Mediated RNA Editing. Front Cell Dev Biol. 2021 Jun 11;9:667879. doi: 10.3389/fcell.2021.667879. PMID: 34178991; PMCID: PMC8226256.

Revision as of 00:25, 29 September 2024


CasRx It’s an inducible endonuclease protein that can target any RNA sequence complementary to a gRNA. It contains an HA tag for Western blot and Immunohistochemistry analysis, and a mchery reporter with an NLS for separating activity between CasRx and the target RNA.


Sequence and Features


Assembly Compatibility:
  • 10
    INCOMPATIBLE WITH RFC[10]
    Illegal EcoRI site found at 499
    Illegal EcoRI site found at 919
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal EcoRI site found at 499
    Illegal EcoRI site found at 919
    Illegal NotI site found at 2908
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal EcoRI site found at 499
    Illegal EcoRI site found at 919
    Illegal BamHI site found at 2899
    Illegal XhoI site found at 2374
  • 23
    INCOMPATIBLE WITH RFC[23]
    Illegal EcoRI site found at 499
    Illegal EcoRI site found at 919
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal EcoRI site found at 499
    Illegal EcoRI site found at 919
    Illegal NgoMIV site found at 187
  • 1000
    COMPATIBLE WITH RFC[1000]


ecision in targeting specific RNA sequences. As a viral protein, CasRx operates independently of the host's cellular machinery, which reduces variability and enhances efficiency.

CasRx is the smallest member of the RNA-targeting CRISPR family, allowing for easier delivery into cells while maintaining high specificity and efficiency in cleaving target RNA. Its minimal off-target effects and high efficiency make it ideal for large-scale transcriptome screening, precise gene silencing, and targeting viral RNA in therapeutic applications.

A key advantage of CasRx over other CRISPR systems is its simplicity--it does not require a PAM sequence or a tracrRNA, making it one of the most straightforward CRISPR systems to implement. CasRx can target virtually any RNA sequence when paired with a guide RNA (gRNA) that is complementary to the target.


Konermann S, Lotfy P, Brideau NJ, Oki J, Shokhirev MN, Hsu PD. Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors. Cell. 2018 Apr 19;173(3):665-676.e14. doi: 10.1016/j.cell.2018.02.033. Epub 2018 Mar 15. PMID: 29551272; PMCID: PMC5910255. Chuang YF, Wang PY, Kumar S, Lama S, Lin FL, Liu GS. Methods for in vitro CRISPR/CasRx-Mediated RNA Editing. Front Cell Dev Biol. 2021 Jun 11;9:667879. doi: 10.3389/fcell.2021.667879. PMID: 34178991; PMCID: PMC8226256.